Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cambridge Laboratories launches Xenazina in Italy

Cambridge Laboratories launches Xenazina in Italy

23rd November 2007

Cambridge Laboratories has announced that its distribution partner Chiesi Group has launched its dopamine depleting agent Xenazina in Italy following approval by the Agenzia Italiana del Farmaco.

The launch marks the third major roll-out for Xenazina with successful launches of the product in Germany and France.

Xenazina (tetrabenazine, also known as Xenazine) has been approved for the treatment of movement disorders associated with Huntington’s disease as well as for the treatment of moderate to severe tardive dyskinesia.

Mark Evans, chief executive officer of Cambridge, expressed the company’s delight in the Italian launch, confirming that it continued the successful roll-out of Xenazine in Europe.

“We are very excited about the opportunities within the European central nervous system market and the commercialisation of Xenazina further strengthens Cambridge’s position within this important field,” he added.

Cambridge licensed Xenazina exclusively to Chiesi in 2003 for the commercialisation of the product in Italy, though the UK pharmaceutical company continues to own worldwide rights to tetrabenazine.

Earlier this year, Cambridge announced that it was to restructure its commercial operations in the UK, with the company establishing two distinct business units in oncology and the central nervous system.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.